Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)

Background: Grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET) are poorly characterized in terms of molecular features and response to treatments. Methods: Patients with G3 GEP-NET were included if they received capecitabine and temozolomide (CAPTEM) or oxaliplatin with either 5-flu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamberti, Giuseppe, Prinzi, Natalie, Bongiovanni, Alberto, Torniai, Mariangela, Andrini, Elisa, de Biase, Dario, Malvi, Deborah, Mosca, Mirta, Berardi, Rossana, Ibrahim, Toni, Pusceddu, Sara, Campana, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178589/
https://www.ncbi.nlm.nih.gov/pubmed/37174986
http://dx.doi.org/10.3390/diagnostics13091595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178589/
https://www.ncbi.nlm.nih.gov/pubmed/37174986
http://dx.doi.org/10.3390/diagnostics13091595

Ejemplares similares